Humoral SARS-CoV-2 immunogenicity wanes 3 months after heterologous inactivated vaccine followed by ChAdOx1 nCoV-19 in autoimmune rheumatic diseases
Asian Pacific Journal of Allergy and Immunology · 2025
DOI: 10.12932/ap-280722-1420 ↗Kurz gefasst
Fachartikel in der Zeitschrift Asian Pacific Journal of Allergy and Immunology, 2025. Verfasst von Parichat Uea-Areewongsa und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand. Hauptthemen laut MEDLINE: COVID-19 Vaccines, SARS-CoV-2, COVID-19, Antibodies, Viral.
Abstract (Originalsprache)
BACKGROUND: Alongside vaccine hesitancy, impaired and waning immunity in autoimmune rheumatic diseases (ARDs) are barriers to immunization. The timeframe of immunity waning in ARD remains unclear. OBJECTIVE: We aimed to examine the waning of humoral immunogenicity in a cohort of ARD patients who received the heterologous inactivated vaccine followed by the adenoviral vector SAR-CoV-2 vaccine at a 3-month follow-up. METHODS: The levels of SARS-CoV-2 anti-RBD IgG were evaluated at 1 and 3 months in adults with ARDs (n = 29) and age- and sex-matched healthy controls (HC) that received the heterologous prime-boost CoronaVac vaccine followed by the ChAdOx1 nCoV-19 vaccine. Seropositivity was defined as anti-receptor binding domain (RBD) IgG levels of ≥ 7.15 binding antibody units (BAU)/mL. The kinetic properties of the vaccines were evaluated based on the ratio of anti-RBD IgG values obtained at each follow-up. Disease activity was evaluated. RESULTS: The seropositivity rate was lower among patients with ARDs than among HCs (89.7% vs. 100%, p = 0.237). At 3 months, the median (IQR) anti-RBD IgG level was lower among patients with ARDs than among HCs (122.3 [30.6, 247.8] vs. 294.2 [127.4,605.7] BAU/mL, p = 0.006). Mean antibody levels in patients with ARDs decreased 3.5 (1.9)-fold within 3 months post-vaccination (122.3 [30.6, 247.8] vs. 279.9 [86,1076.5] BAU/mL, p < 0.001). Disease flare-ups occurred in three patients. CONCLUSIONS: Our findings included changes to anti-RBD IgG levels and may inform vaccination strategies. SAR-CoV2 vaccine-induced immunity was lower in patients with ARDs than in HCs and decreased within 3 months, suggesting a need for booster vaccinations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand.
- Department of Biomedical Sciences and Biomedical Engineering, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand.
- Department of Pathology, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand.
Zitieren
APA
Uea-Areewongsa, P., Pinpathomrat, N., Ongarj, J., Sophonmanee, R., Seepathomnarong, P., Seeyankem, B., Surasombatpattana, S., & Intapiboon, P. (2025). Humoral SARS-CoV-2 immunogenicity wanes 3 months after heterologous inactivated vaccine followed by ChAdOx1 nCoV-19 in autoimmune rheumatic diseases. Asian Pacific Journal of Allergy and Immunology. https://doi.org/10.12932/ap-280722-1420
Vancouver
Uea-Areewongsa P, Pinpathomrat N, Ongarj J, Sophonmanee R, Seepathomnarong P, Seeyankem B, et al. Humoral SARS-CoV-2 immunogenicity wanes 3 months after heterologous inactivated vaccine followed by ChAdOx1 nCoV-19 in autoimmune rheumatic diseases. Asian Pacific Journal of Allergy and Immunology. 2025. doi:10.12932/ap-280722-1420
BibTeX
@article{UeaAreewongsa2025,
author = {Uea-Areewongsa, Parichat and Pinpathomrat, Nawamin and Ongarj, Jomkwan and Sophonmanee, Ratchanon and Seepathomnarong, Purilap and Seeyankem, Bunya and Surasombatpattana, Smonrapat and Intapiboon, Porntip},
title = {Humoral SARS-CoV-2 immunogenicity wanes 3 months after heterologous inactivated vaccine followed by ChAdOx1 nCoV-19 in autoimmune rheumatic diseases},
journal = {Asian Pacific Journal of Allergy and Immunology},
year = {2025},
doi = {10.12932/ap-280722-1420}
}
EUVIMED